Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NR4A2 | P43354 | 7/20 | 0.63 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30167982 | 0.91 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL9803295 | 0.91 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL10787479 | 0.91 | KMT2A (0.80) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL4799598 | 0.90 | KMT2A (0.69) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL4653545 | 0.90 | KMT2A (0.69) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL4509654 | 0.89 | KMT2A (0.77) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL31133401 | 0.88 | KMT2A (0.71) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL19983022 | 0.88 | KMT2A (0.71) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL6932542 | 0.87 | KMT2A (0.75) | KMT2ANR4A2AKR1C3PLA2G4BNR1H4 | |
| SCHEMBL7635135 | 0.86 | GAA (0.73) | KMT2ANR4A2GAAALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480761-A | CHROMOGENIC PHOTOGRAPHIC ELEMENTS WITH DIFFUSION TRANSFER | EASTMAN KODAK COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEAGEN INC (US) | 2024-09-05 | — | — | US | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | SEAGEN INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | SEAGEN INC. (US) | 2023-05-02 | — | — | US | disclosed |
| US-20220243045-A1 | THERMOPLASTIC RESIN COMPOSITION, MOLDED ARTICLE, AND PRODUCT | MITSUBISHI ELECTRIC CORPORATION (JP) | 2022-08-04 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | SEATTLE GENETICS, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3615081-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | Seattle Genetics, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-01 | — | — | US | disclosed |
| EP-2807162-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-12-03 | — | — | EP | disclosed |
| WO-2013110590-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-08-01 | — | — | WO | disclosed |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-25 | — | — | US | disclosed |
| EP-0910688-A1 | FIBERS WITH OPTICAL FUNCTION | NISSAN MOTOR COMPANY, LIMITED (JP) | 1999-04-28 | — | — | EP | disclosed |
| WO-1998050609-A1 | FIBERS WITH OPTICAL FUNCTION | NISSAN MOTOR CO., LTD. (JP) | 1998-11-12 | — | — | WO | disclosed |
| US-5214049-A | Blend of polyphenylene ether, thermoplastic polyester and a hydroxycarboxylic acid or derivative; workability; solvent resistance; mechanical properties | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1993-05-25 | — | — | US | disclosed |
| EP-0368283-A2 | Resin composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-05-16 | — | — | EP | disclosed |
| EP-0073437-B1 | DYED POLYESTER FIBER COMPOSITE STRUCTURE | TEIJIN LIMITED (JP) | 1987-05-20 | — | — | EP | disclosed |
| EP-0022182-B1 | SYNTHETIC POLYESTER PULP AND PROCESS FOR PREPARING SAME | TEIJIN LIMITED (JP) | 1984-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931414-B2 | Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates | NAMPT, NNMT, NADK | KMT2A 1408/4885NR4A2 1947/4885AKR1C3 1334/4885 |
| US-20150005288-A1 | SUBSTITUTED PHENYLIMIDAZOPYRAZOLES AND USE THEREOF | VHL, FLT4, FLT1 | KMT2A 3556/4885NR4A2 878/4885AKR1C3 2454/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | KMT2A 2535/4885NR4A2 997/4885AKR1C3 1847/4885 |
| US-20200197524-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | KMT2A 1408/4885NR4A2 1947/4885AKR1C3 1334/4885 |
| US-20240293554-A1 | QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES | NAMPT, NNMT, NADK | KMT2A 1408/4885NR4A2 1947/4885AKR1C3 1334/4885 |
| US-20130190290-A1 | Substituted phenylimidazopyrazoles and their use | VHL, FLT4, FLT1 | KMT2A 3543/4885NR4A2 790/4885AKR1C3 2557/4885 |
| US-11638762-B2 | Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors | NAMPT, NME4, NNMT | KMT2A 3195/4885NR4A2 1357/4885AKR1C3 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.